5 citations,
November 2022 in “Animal Genetics” Genomic research can help improve the quality and production of natural fibers in animals.
1 citations,
January 2021 in “Wits Journal of Clinical Medicine” Long COVID causes lasting symptoms and needs ongoing care.
June 2023 in “Nephrology Dialysis Transplantation” Enteric hyperoxaluria can cause severe kidney failure after bowel surgery.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A patient with a PLEC mutation has epidermolysis bullosa, muscular dystrophy, and myasthenia gravis, which improved with steroid treatment.
176 citations,
August 1981 in “JAMA” Toxic Shock Syndrome mainly affects menstruating women, can recur, and is linked to staph bacteria, with rapid treatment being crucial.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
The document concludes that severe trauma can cause temporary hair loss, known as Telogen Effluvium, which usually resolves without treatment.
January 1982 in “Journal of The American Academy of Dermatology” Experts discussed treatments for skin conditions in children, emphasizing hydration, cautious medication use, and early intervention for infections.
January 2018 in “Indian Dermatology Online Journal” DM and AA may share a common cause.
29 citations,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
2 citations,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.